R-MA regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Methotrexate-Cytarabine (Ara C) regimen
Overview
R-MA regimen refers to a regimen consisting of rituximab, methotrexate, and cytarabine (Ara C) used to treat mantle cell lymphoma.[1]
Regimen
RRituximab
MMethotrexate
ACytarabine (Ara-C)
Indications
References
- ↑ 1.0 1.1 Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R; et al. (2013). “A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213”. Ann Oncol. 24 (6): 1587–93. doi:10.1093/annonc/mdt070. PMC 3660082. PMID 23504948.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH